Cargando…

Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model

Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell-surface immunoreceptor expressed on microglia, osteoclasts, dendritic cells and macrophages. Heterozygous loss-of-function mutations in TREM2, including mutations enhancing shedding form the cell surface, have been associated with my...

Descripción completa

Detalles Bibliográficos
Autores principales: Beckmann, Nicolau, Neuhaus, Anna, Zurbruegg, Stefan, Volkmer, Pia, Patino, Claudia, Joller, Stefanie, Feuerbach, Dominik, Doelemeyer, Arno, Schweizer, Tatjana, Rudin, Stefan, Neumann, Ulf, Berth, Ramon, Frieauff, Wilfried, Gasparini, Fabrizio, Shimshek, Derya R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909920/
https://www.ncbi.nlm.nih.gov/pubmed/36755323
http://dx.doi.org/10.1186/s12974-022-02671-z
_version_ 1784884677105942528
author Beckmann, Nicolau
Neuhaus, Anna
Zurbruegg, Stefan
Volkmer, Pia
Patino, Claudia
Joller, Stefanie
Feuerbach, Dominik
Doelemeyer, Arno
Schweizer, Tatjana
Rudin, Stefan
Neumann, Ulf
Berth, Ramon
Frieauff, Wilfried
Gasparini, Fabrizio
Shimshek, Derya R.
author_facet Beckmann, Nicolau
Neuhaus, Anna
Zurbruegg, Stefan
Volkmer, Pia
Patino, Claudia
Joller, Stefanie
Feuerbach, Dominik
Doelemeyer, Arno
Schweizer, Tatjana
Rudin, Stefan
Neumann, Ulf
Berth, Ramon
Frieauff, Wilfried
Gasparini, Fabrizio
Shimshek, Derya R.
author_sort Beckmann, Nicolau
collection PubMed
description Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell-surface immunoreceptor expressed on microglia, osteoclasts, dendritic cells and macrophages. Heterozygous loss-of-function mutations in TREM2, including mutations enhancing shedding form the cell surface, have been associated with myelin/neuronal loss and neuroinflammation in neurodegenerative diseases, such as Alzheimer`s disease and Frontotemporal Dementia. Using the cuprizone model, we investigated the involvement of soluble and cleavage-reduced TREM2 on central myelination processes in cleavage-reduced (TREM2-IPD), soluble-only (TREM2-sol), knockout (TREM2-KO) and wild-type (WT) mice. The TREM2-sol mouse is a new model with selective elimination of plasma membrane TREM2 and a reduced expression of soluble TREM2. In the acute cuprizone model demyelination and remyelination events were reflected by a T2-weighted signal intensity change in magnetic resonance imaging (MRI), most prominently in the external capsule (EC). In contrast to WT and TREM2-IPD, TREM2-sol and TREM2-KO showed an additional increase in MRI signal during the recovery phase. Histological analyses of TREM2-IPD animals revealed no recovery of neuroinflammation as well as of the lysosomal marker LAMP-1 and displayed enhanced cytokine/chemokine levels in the brain. TREM2-sol and, to a much lesser extent, TREM2-KO, however, despite presenting reduced levels of some cytokines/chemokines, showed persistent microgliosis and astrocytosis during recovery, with both homeostatic (TMEM119) as well as activated (LAMP-1) microglia markers increased. This was accompanied, specifically in the EC, by no myelin recovery, with appearance of myelin debris and axonal pathology, while oligodendrocytes recovered. In the chronic model consisting of 12-week cuprizone administration followed by 3-week recovery TREM2-IPD displayed sustained microgliosis and enhanced remyelination in the recovery phase. Taken together, our data suggest that sustained microglia activation led to increased remyelination, whereas microglia without plasma membrane TREM2 and only soluble TREM2 had reduced phagocytic activity despite efficient lysosomal function, as observed in bone marrow-derived macrophages, leading to a dysfunctional phenotype with improper myelin debris removal, lack of remyelination and axonal pathology following cuprizone intoxication. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02671-z.
format Online
Article
Text
id pubmed-9909920
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99099202023-02-10 Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model Beckmann, Nicolau Neuhaus, Anna Zurbruegg, Stefan Volkmer, Pia Patino, Claudia Joller, Stefanie Feuerbach, Dominik Doelemeyer, Arno Schweizer, Tatjana Rudin, Stefan Neumann, Ulf Berth, Ramon Frieauff, Wilfried Gasparini, Fabrizio Shimshek, Derya R. J Neuroinflammation Research Triggering receptor expressed on myeloid cells 2 (TREM2) is a cell-surface immunoreceptor expressed on microglia, osteoclasts, dendritic cells and macrophages. Heterozygous loss-of-function mutations in TREM2, including mutations enhancing shedding form the cell surface, have been associated with myelin/neuronal loss and neuroinflammation in neurodegenerative diseases, such as Alzheimer`s disease and Frontotemporal Dementia. Using the cuprizone model, we investigated the involvement of soluble and cleavage-reduced TREM2 on central myelination processes in cleavage-reduced (TREM2-IPD), soluble-only (TREM2-sol), knockout (TREM2-KO) and wild-type (WT) mice. The TREM2-sol mouse is a new model with selective elimination of plasma membrane TREM2 and a reduced expression of soluble TREM2. In the acute cuprizone model demyelination and remyelination events were reflected by a T2-weighted signal intensity change in magnetic resonance imaging (MRI), most prominently in the external capsule (EC). In contrast to WT and TREM2-IPD, TREM2-sol and TREM2-KO showed an additional increase in MRI signal during the recovery phase. Histological analyses of TREM2-IPD animals revealed no recovery of neuroinflammation as well as of the lysosomal marker LAMP-1 and displayed enhanced cytokine/chemokine levels in the brain. TREM2-sol and, to a much lesser extent, TREM2-KO, however, despite presenting reduced levels of some cytokines/chemokines, showed persistent microgliosis and astrocytosis during recovery, with both homeostatic (TMEM119) as well as activated (LAMP-1) microglia markers increased. This was accompanied, specifically in the EC, by no myelin recovery, with appearance of myelin debris and axonal pathology, while oligodendrocytes recovered. In the chronic model consisting of 12-week cuprizone administration followed by 3-week recovery TREM2-IPD displayed sustained microgliosis and enhanced remyelination in the recovery phase. Taken together, our data suggest that sustained microglia activation led to increased remyelination, whereas microglia without plasma membrane TREM2 and only soluble TREM2 had reduced phagocytic activity despite efficient lysosomal function, as observed in bone marrow-derived macrophages, leading to a dysfunctional phenotype with improper myelin debris removal, lack of remyelination and axonal pathology following cuprizone intoxication. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02671-z. BioMed Central 2023-02-08 /pmc/articles/PMC9909920/ /pubmed/36755323 http://dx.doi.org/10.1186/s12974-022-02671-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Beckmann, Nicolau
Neuhaus, Anna
Zurbruegg, Stefan
Volkmer, Pia
Patino, Claudia
Joller, Stefanie
Feuerbach, Dominik
Doelemeyer, Arno
Schweizer, Tatjana
Rudin, Stefan
Neumann, Ulf
Berth, Ramon
Frieauff, Wilfried
Gasparini, Fabrizio
Shimshek, Derya R.
Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model
title Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model
title_full Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model
title_fullStr Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model
title_full_unstemmed Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model
title_short Genetic models of cleavage-reduced and soluble TREM2 reveal distinct effects on myelination and microglia function in the cuprizone model
title_sort genetic models of cleavage-reduced and soluble trem2 reveal distinct effects on myelination and microglia function in the cuprizone model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909920/
https://www.ncbi.nlm.nih.gov/pubmed/36755323
http://dx.doi.org/10.1186/s12974-022-02671-z
work_keys_str_mv AT beckmannnicolau geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT neuhausanna geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT zurbrueggstefan geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT volkmerpia geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT patinoclaudia geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT jollerstefanie geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT feuerbachdominik geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT doelemeyerarno geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT schweizertatjana geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT rudinstefan geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT neumannulf geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT berthramon geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT frieauffwilfried geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT gasparinifabrizio geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel
AT shimshekderyar geneticmodelsofcleavagereducedandsolubletrem2revealdistincteffectsonmyelinationandmicrogliafunctioninthecuprizonemodel